.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,261,547

« Back to Dashboard

Details for Patent: 6,261,547

Title: Gelling ophthalmic compositions containing xanthan gum
Abstract:Ophthalmic drug delivery vehicles which are administrable as a liquid and which gel upon contact with the eye are disclosed. The vehicles contain xanthan gum and an ophthalmically acceptable anesthetic agent.
Inventor(s): Bawa; Rajan (Fort Collins, CO), Hall; Rex E. (Fort Worth, TX), Kabra; Bhagwati P. (Arlington, TX), Teague; James E. (Arlington, TX), Cagle; Gerald D. (Fort Worth, TX), Markwardt; Kerry L. (Mansfield, TX), Shah; Mandar V. (Fort Worth, TX)
Assignee: Alcon Manufacturing, Ltd. (Fort Worth, TX)
Filing Date:Nov 23, 1999
Application Number:09/448,038
Claims:1. An ophthalmic composition having a total ionic strength of about 120 mM or less and comprising an ophthalmically acceptable anesthetic drug and xanthan gum, wherein the xanthan gum has an initial bound acetate content of at least about 4% and an initial bound pyruvate content of at least about 2.5%, provided that the composition does not contain locust bean gum.

2. The composition of claim 1 wherein the amount of xanthan gum is from about 0.3 to about 0.8% (w/v).

3. The composition of claim 1 further comprising one or more agents selected from the group consisting of buffering agents; tonicity-adjusting agents; surfactants; solubilizing agents; stabilizing agents; comfort-enhancing agents; emollients; pH-adjusting agents; and lubricants.

4. The composition of claim 1 wherein the xanthan gum forms a gel having an elastic modulus (G') of approximately 130 Pa when measured in the Lysozyme Gel Strength Test.

5. The composition of claim 1 wherein the composition has a total ionic strength of about 94 mM or less.

6. An unpreserved, unit-dose ophthalmic composition having a total ionic strength of about 120 mM or less and comprising an ophthalmically acceptable anesthetic drug and xanthan gum, wherein the xanthan gum has an initial bound acetate content of at least about 4% and an initial bound pyruvate content of at least about 2.5%, provided that the composition does not contain locust bean gum or a preservative.

7. The composition of claim 6 wherein the anesthetic drug is selected from the group consisting of proparacaine; lidocaine; cocaine; oxybuprocaine; benoxinate; butacaine; mepivacaine; etidocaine; dibucaine; bupivacaine; levobupivacaine; tetracaine; and procaine.

8. The composition of claim 7 wherein the anesthetic drug is selected from the group consisting of levobupivacaine; proparacaine and tetracaine.

9. An unpreserved, unit-dose ophthalmic composition having a total ionic strength of about 120 mM or less, a pH of about 6-8, and comprising

a) 0.2-1.5% (w/v) of an ophthalmically acceptable anesthetic drug;

b) 0.3-0.8% (w/v) of xanthan gum having an initial bound acetate content of at least about 4% and an initial bound pyruvate content of at least about 2.5%;

c) a buffering agent; and

d) a tonicity adjusting agent in an amount sufficient to cause the composition to have an osmolality of 250-350 mOsm/Kg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc